RE:RE:a second formulation of avenanthramides pillsHopeforthebest wrote: Thnk you Used PROPHYLATIC for pointing out ANOTHER MISSED opportunity by gagnon.
Not missed at all. We are watching history unfold. No one else in the history of humanity has been able to deliver what CZO has in its pharma-grade avenanthramide pill. Avenanthramide was why Gilles originally joined CZO and now he has initiated the clinical trial process with an influencial clinical trial investigator at the Montreal Heart Institute. Rather than just do a Phase I clinical trial CZO has filed an amendment for a Phase I clinical trial that can go from Phase I into Phase II. There will be no need to go through a laborious Health Canada regulatory approval process to get into Phase II. This will save time on the other side of Phase I.
CZO will also be able to test other formulations of its pill, it appears, and Gilles has talked about even potentially testing those with inflammation in Phase II providing valuable data that could hint to efficacy. With safety likely in the bag data given the history of avenanthramide and CZO's product hints of efficacy could be valuable as CZO then potentially licenses the technology. The other formulations may include CZO's next-generation carriers; at least Gilles has talked about potentially using a newer carrier in the past. The details of the coming Health Canada approval could be interesting. The Angiogenesis Foundation has also conducted certain trials with CZO's avenanthramide.
Nov. 9, 2022 News Release: "Clinical Trial:
Subsequent to quarter, the Company received an Acknowledgement Letter from Health Canada confirming complete information and material to support a Clinical Trial Application (CTA) for Phase 1/2a study entitled “Ceapro Inc Avenanthramide (AVA): A Double-Blind, Placebo-Controlled, Randomized, Adaptive, First-in-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Avenanthramide (AvenActive).”